Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of MMV371 Long-Acting Injection in Healthy Participants
NCT06558643Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CBE161 in malaria (4 cohorts), sponsored by Medicines for Malaria Venture. Primary endpoint: Number of participants with adverse events. Started Aug 2024; status: completed.
02
Drugs
CBE161
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06558643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558643.